Jean‐François Martini

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Alain Ravaud, Robert J. Motzer, Hardev Pandha et al. · New England Journal of Medicine · 2016 · 777 citations

Medicine, Oncology, Pharmacotherapy +17

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Alice T. Shaw, Enriqueta Felip, Todd M. Bauer et al. · The Lancet Oncology · 2017 · 649 citations · Full text

Medicine, Oncology, Pharmacology +14

<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

Alice T. Shaw, Benjamin Solomon, Benjamin Besse et al. · Journal of Clinical Oncology · 2019 · 379 citations · Full text

Medicine, Oncology, Pharmacology +17

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

Alice T. Shaw, Benjamin Solomon, Rita Chiari et al. · The Lancet Oncology · 2019 · 352 citations

Medicine, Oncology, Pharmacology +11

Increased Expression of Prolactin Receptor Gene Assessed by Quantitative Polymerase Chain Reaction in Human Breast Tumors Versus Normal Breast Tissues

Philippe Touraine, Jean‐François Martini, B Zafrani et al. · The Journal of Clinical Endocrinology & Metabolism · 1998 · 171 citations · Full text

Life Sciences, Molecular Biology, Oncology +16